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We read with great interest the recent article of Boccara et al. (1)
in the Journal calling for a better understanding of HIV and
oronary heart disease (CHD). The author’s in-depth summary
panned the epidemiology of CHD among people living with
IV, traditional cardiovascular risk factors in this population,
athophysiology, outcomes, and strategies toward prevention and
reatment. What was unfortunately absent, however, was any
ention of the relationship between HIV and cardiovascular
isease where the burden of HIV is greater than anywhere else on
he planet—sub-Saharan Africa.
Although CHD is rarely reported among Africans with HIV, a
iscussion of the relationship of the 2 disorders should not ignore
he region of the world where HIV is most rampant, cardiovascular
isease risk factors are becoming more prevalent, and the life
xpectancy of those with HIV is lengthening. Of the 34 million
eople living with HIV worldwide, 69% (23.5 million) live in
ub-Saharan Africa (2). Over the last few decades, it has become
lear that chronic cardiovascular diseases and risk factors are on the
ise on the African continent (3). For example, a systematic
nalysis of health examination surveys and epidemiological studies
howed that mean systolic blood pressure increased in Africa
etween 1980 and 2008 (4). A Ugandan study showed that
IV-seropositive patients on combined antiretroviral therapy
ould achieve a normal life expectancy (5) and the accompanying
xposure to risk for developing chronic cardiovascular diseases.
There are a number of other reasons why the experiences in
ub-Saharan Africa must be considered in this context, including
ifferences in the common HIV subtypes with known effects on
ndothelial function (6), the growing burden of traditional cardio-
ascular risk factors among HIV-seropositive Africans (7,8), and in
ontrast to the experiences in the West, lower smoking rates in
ub-Saharan Africa than most other regions of the world (9).
astly, although combined antiretroviral therapy is provided by
nternational donors, there is disproportionately little attention and
unding for noncommunicable diseases on the continent (10). An
ntenable disparity exists whereby individuals needing services for
IV and cardiovascular disease in sub-Saharan Africa have free
ccess to the former but little or none to the latter.
The issues surrounding HIV and cardiovascular disease in
ub-Saharan Africa are complex but demand urgent attention
hile the many factors promoting CHD are still nascent. We are
n need of a better and broader understanding of HIV and chronic
ardiovascular diseases. For this reason, we should apply the
pocryphal Sutton law to this paradigm. If we want to understand
ow HIV affects the cardiovascular system, we should go where the
IV is.
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Reply
We thank Drs. Bloomfield and Velazquez for their letter in
reference to our review article (1). The researchers pointed out that
the discussion on coronary heart disease (CHD) in HIV-infected
sub-Saharan Africans was absent in our review. In fact, sub-
Saharan Africa is now facing a double burden of disease, in which
patients are suffering from noncommunicable diseases such as
CHD along with the current HIV epidemic. Whether the pres-
ence of HIV places patients at higher risk of CHD remains to be
clarified. Cardiovascular disease and HIV infection in sub-Saharan
African countries are predominantly linked to advanced immuno-
suppression (2). As stated by Ntsekhe and Mayosi (3), “the three
factors that influence the frequency and pattern of cardiac mani-
festations in people infected with HIV in Africa are geography,
access to HAART, and the degree of immunosuppression.”
Pericarditis (with Mycobacterium tuberculosis being responsible
for more than 85% of cases) and cardiomyopathy (mainly from
nonischemic causes) are the leading causes of cardiovascular
manifestations in sub-Saharan Africa, where more than 23 million
inhabitants are infected with HIV (3–6). In contrast, there is a
paucity of reports addressing the prevalence and spectrum of CHD
in HIV-infected patients in Africa, but this should not diminish
their impact or importance. The Heart of Soweto study is the
largest cohort study of heart disease in Africa and is being
conducted in South Africa, where 5 million individuals are infected
with HIV (7). Many studies have been published by this group
